- Global Pharma News & Resources

Bivalent Human Papillomavirus Vaccine Market Size, Share, Growth Drivers and Opportunities 2023 to 2032 | insightSLICE

The human papillomavirus (HPV), which is spread through sexual contact, has been related to oropharyngeal as well as other anogenital cancers in addition to cervical cancer. The viral species types 16 and 18 are responsible for the majority of HPV-related cancers.

Due to this, first-generation vaccinations are built on systems that manufacture virus-like particles from the recombinant production of L1 (VLPs). The quadrivalent vaccine (4vHPV) also contained L1 VLPs of HPV-6 and -11, which are mainly linked to anogenital warts, but they were concentrated on HPV-16 and -18.

Access the sample report:

The key players of the Global Bivalent Human Papillomavirus Vaccine Market are:

Numerous businesses are heavily investing in the development of additional HPV vaccines for all age groups. In which the availability of vaccinations is limited, and the demand is growing quickly.

As a result, businesses are investing in the creation of a new vaccine against the human papillomavirus with the assistance of the federal government, which would be expected to expand the market for investment opportunities.

Additionally, the emergence of new disorders will lead to greater financing for R&D projects, a strong pipeline, and fresh opportunities for vaccination for a wide range of demographic groups.

Walvax, GSK, InnoVax, Merck & Co Inc, HumanWell Healthcare, ZSSW, Serum Institute of India, and other major companies are participating in the global market for bivalent human papillomavirus vaccines.

Read more about the report inclusions:

Bivalent HPV vaccines are preferred by the clinicians:

Altogether, the US Food and Drug Administration has granted licenses for the 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccination. The majority of HPV malignancies are caused by HPV types 16 and 18, which are protected against by all three HPV vaccinations.

owing to the prevalence of two main groups of HPV viruses and their shared characteristics. The most prevalent forms are the ones that the bivalent human papillomavirus vaccinations are designed to prevent.

Some disorders brought on by specific kinds of human papillomavirus (HPV) are prevented by the bivalent recombinant HPV vaccine. The vaccine offers a defense against two distinct HPV strains.

Market report for HPV vaccines:

The Bivalent Human Papillomavirus Vaccine research report provides competitive response estimations for the years 2019 to 2032. The report uses the historic years 2019, 2020 and 2021, the base year of 2022, and the forecast years from 2023 to 2032 for the calculations.

The market for human papillomavirus vaccines is expanding along with the incidence of diseases caused by the virus. The market for human papillomavirus (HPV) vaccinations is growing as a result of the creation of novel HPV vaccines and greater efforts by governmental and private groups for advanced screening and vaccination.

In the upcoming years, it is anticipated that the market will continue to expand steadily due to rising HPV-related cancers in the perineal, nasopharyngeal, and vaginal areas, as well as a growing preference for HPV vaccines to help prevent infections.

Factors affecting the growth:

On the other side, rising healthcare costs are a result of a push for prevention. Over the past 20 years, the cost of vaccinations has grown from the single figures to the triple figures multiple times, creating significant problems for physicians and their clients as well as placing pressure on public health financing.

Additionally, viral infections are among the leading causes of death worldwide and present some of the most pressing security and health concerns. Throughout the world, infectious diseases are some of the most common causes of mortality.

Proceed to purchase:

To stop and regulate the spread of these illnesses through preventive vaccines, researchers from all around the world are presently conducting research, sharing information, enhancing laboratory capability in developing nations, and establishing worldwide surveillance networks.

Increased government measures are anticipated to accelerate market expansion across the forecast timeline.

A significant hindrance for the worldwide human papillomavirus market in the anticipated term is anticipated to be the vaccine’s accessibility to patients at the appropriate moment.

Additionally, creating vaccinations is a costly process. From in vitro research to commercialization, the development phase requires ten to twenty years and expenditures of around $800 million and $1 billion. All of these variables might limit market expansion.

Global Bivalent Human Papillomavirus Vaccine Market Key Segments:

By Product Type

  • HPV16
  • HPV18

By Application

  • 9-16 Years Old
  • 16-20 Years Old
  • 20-26 Years Old
  • 26-45 Years Old

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Related reports:

Global Nuclear Imaging Equipment Market:

Global Orthopedic Bone Cement Market:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 25-Jan-2023